Plasma Epstein-Barr virus DNA for the prediction of treatment response and disease progression in non-keratinizing differentiated nasopharyngeal carcinoma
Our study highlights the aggressive nature of DNKC, characterized by early recurrence. EBV-DNA levels may serve as a biomarker to monitor treatment response, prognostic prediction, and recurrence surveillance.
Authors
- Yunxia Huang (ORCID: https://orcid.org/0000-0002-8542-9804)
- Guanzhong Lu (ORCID: https://orcid.org/0000-0003-2031-785X)
- Lin-Feng Guo (ORCID: https://orcid.org/0009-0008-6696-8096)
- Zhen-Zhen Lu (ORCID: https://orcid.org/0009-0007-0600-4810)
- Yi‐Feng Yu (ORCID: https://orcid.org/0000-0001-9404-2639)
- San‐Gang Wu
- Qin Lin (ORCID: https://orcid.org/0000-0002-6479-9590)
Institutions
- First Affiliated Hospital of Xiamen University (CN)
Publication Details
- Journal
- Infectious Agents and Cancer
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1186/s13027-025-00661-3
- Citations
- 3
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 3.14